Tacrolimus Dose Requirement in Pediatric Liver Transplantation: Influence of CYP3A5 Gene Polymorphism

• Fouquet V , AlvesA, BranchereauS et al. Long-term outcome of pediatric liver transplantation for biliary atresia: a 10-year follow-up in a single center. Liver Transpl. 11(2) , 152–160 (2005).
   PubMed Web of Science ®Google Scholar
• Kelly D . Safety and efficacy of tacrolimus in pediatric liver recipients. Pediatr. Transplant.15(1) , 19–24 (2010).
   PubMed Web of Science ®Google Scholar
• Kelly D , JaraP, RodeckB et al. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet 364(9439) , 1054–1061 (2004).
   PubMed Web of Science ®Google Scholar
• Anglicheau D , VerstuyftC, Laurent-PuigP et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 14(7) , 1889–1896 (2003).
   PubMed Web of Science ®Google Scholar
• Fukudo M , YanoS, MasudaS et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin. Pharmacol. Ther. 80 , 331–345 (2006).
   PubMed Web of Science ®Google Scholar
• Zheng H , WebberS, ZeeviA et al. Tacrolimus dosing in pediatric heart transplant patients is related to cyp3a5 and mdr1 gene polymorphisms. Am. J. Transplant. 3(4) , 477–483 (2003).
   PubMed Web of Science ®Google Scholar
• Zhao W , ElieV, RousseyG et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin. Pharmacol. Ther. 86(6) , 609–618 (2009).
   PubMed Web of Science ®Google Scholar
• Goto M , MasudaS, KiuchiT et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics14(7) , 471–478 (2004).
   PubMedGoogle Scholar
• Wei-Lin W , JingJ, Shu-SenZ et al. Tacrolimus dose requirement in relation to donor and recipient abcb1 and CYP3A5 gene polymorphisms in chinese liver transplant patients. Liver Transpl. 12 , 775–780 (2006).
   PubMed Web of Science ®Google Scholar
• Masuda S , GotoM, FukatsuS et al. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin. Pharmacol. Ther. 79 , 90–102 (2006).
   PubMed Web of Science ®Google Scholar
• Kuehl P , ZhangJ, LinY et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4) , 383–391 (2001).
   PubMed Web of Science ®Google Scholar
• Thervet E , LoriotMA, BarbierS et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6) , 721–726 (2010).
   PubMed Web of Science ®Google Scholar
• Quteineh L , VerstuyftC. Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients. Curr. Opin. Organ. Transplant.15 , 601–607 (2010).
   PubMed Web of Science ®Google Scholar
• Quteineh L , VerstuyftC, FurlanV et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin. Pharmacol. Toxicol. 103(6) , 546–552 (2008).
   PubMed Web of Science ®Google Scholar
• Briceño J , CiriaR, PleguezueloM et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis c virus cirrhosis. Liver Transpl. 15 , 37–48 (2009).
   PubMed Web of Science ®Google Scholar
• Koçbiyik A , DemirhanB, SevmisS, BudakogluI, KarakayaliH, HaberalM. Role of postreperfusion subcapsular wedge biopsies in predicting initially poor graft function after liver transplantation. Transplant. Proc.41 , 2747–2748 (2009).
   PubMed Web of Science ®Google Scholar
• Busquets J , FiguerasJ, SerranoT et al. Postreperfusion biopsies are useful in predicting complications after liver transplantation. Liver Transpl. 7 , 432–435 (2001).
   PubMed Web of Science ®Google Scholar
• Kakizoe S , YanagaK, StarzlT, DemetrisA. Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury. Hepatology11 , 932–941 (1990).
   PubMed Web of Science ®Google Scholar
• Ferraris J , ArgibayP, CostaL et al. Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: age dependency and pharmacological interaction with steroids. Pediatr. Transplant. 15 , 525–532 (2011).
   PubMed Web of Science ®Google Scholar
• Gijsen V , MitalS, van Schaik RH et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J. Heart Lung Transplant.30(12) , 1352–1359 (2011).
   PubMed Web of Science ®Google Scholar
• Kuypers DR , de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin. Pharmacol. Ther.82(6) , 711–725 (2007).
   PubMed Web of Science ®Google Scholar
• de Wildt SN , van Schaik RH, Soldin OP et al. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur. J. Clin. Pharmacol.67(12) , 1231–1241 (2011).
   PubMed Web of Science ®Google Scholar
• Yu S , WuL, JinJ et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 81(1) , 46–51 (2006).
   PubMed Web of Science ®Google Scholar
• Ji E , ChoiL, SuhKS, ChoJY, HanN, OhJM. Combinational effect of intestinal and hepatic cyp3a5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation94(8) , 866–872 (2012).
   PubMed Web of Science ®Google Scholar
• Naesens M , SalvatierraO, LiL, KambhamN, ConcepcionW, SarwalM. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. Transplantation85(8) , 1139–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Fakhoury M , LitalienC, MedardY et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab. Dispos. 33(11) , 1603–1607 (2005).
   PubMed Web of Science ®Google Scholar
• Kearns GL , Abdel-RahmanSM, AlanderSW, BloweyDL, LeederJS, KauffmanRE. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N. Engl. J. Med.349(12) , 1157–1167 (2003).
   PubMed Web of Science ®Google Scholar
• Kuypers DR , de Jonge H, Naesens M, Vanrenterghem Y. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet. Genomics18(10) , 861–868 (2008).
   PubMed Web of Science ®Google Scholar
• Gibbs MA , ThummelKE, ShenDD, KunzeKL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of ki values and impact of CYP3A5 expression. Drug Metab. Dispos.27(2) , 180–187 (1999).
   PubMed Web of Science ®Google Scholar

▪ Websites

• US FDA: Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm
   Google Scholar
• Diflucan. www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf
   Google Scholar